I am Intellectual Property & Licensing Manager of Thiakis Limited, a privately owned biopharmaceutical company founded in 2004 focused on the development of novel therapeutic approaches for the treatment of obesity and other metabolic diseases.

Thiakis raised £10m (US$19m) in a Series A financing led jointly by Novo A/S and Advent Venture Partners in August 2006, to develop obesity therapies based upon the regulation of appetite by gut hormones resulting from the research of co-founder Professor Steve Bloom at Imperial College London.

Lead products are oxyntomodulin and Peptide YY3-36 (PYY3-36), both of which have been shown to reduce appetite and food intake in studies of human volunteers, and, in the case of oxyntomodulin, weight loss.